arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Royalty Pharma plc

RPRX
$67.54 ▼ -0.02 (-0.03%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
29 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
88
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Royalty Pharma plc shows strong fundamentals with top-quartile Profit Margin (%) and Operating Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $30.1B
Dividend Yield 0.35%
Revenue Growth 16.5% ↗
Op. Margin 19.7% ↘
ROIC 1.5% ↘
FCF / Share $1.64 →
Trailing P/E 1688.5x
Price / Book —
FCF Yield 2.4%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

29-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$674.14M
↑ +16.5% —
Net Income Profit after all expenses
$17.88M
↓ -40.7% —
Operating Margin Operating profit as % of sales
19.7%
↓ -77.9% 99th
FCF / Share Free cash flow per share
$1.64
— -0.5% —
Long-Term Debt Long-term obligations
$8.96B
— +0.1% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↑
98
Financial Health ↓
75
Cash Quality →
92

Dividend History

Dividend / share · sourced from SEC filings
$0.80 Latest / share
+5.3% YoY
+38.7% 4-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 8 years · 29 quarters